Feb. 12 at 1:53 PM
Last night
$NVCR announced the FDA approved the use of their TTFs for certain pancreatic cancers. This appears a meaningful win for NVCR that, as noted on the attachment, otherwise trades at the lowest multiple of analyst consensus revenue estimates of all commercial-stage oncology focused bios.
Investors are cautioned the attachment does not consider gross profit margins on projected sales. TTM NVCR gross margins were roughly 76% where peers on the attachment like
$DAWN generate 89% gross margins on sales.
$IMCR gross margins, by comparison, have been roughly 99%.
We'd also remind NVCR investors just a few days ago NVCR filed an 8K that said roughly
$13MM sales/quarter may be revised due to issues with reimbursement processes. Take a moment to read the 8K
After NVCR,
$AUTL &
$IOVA trade at the lowest multiples of projected FY25 - FY28 sales. Both also generate lower gross margins than traditional ROA (pills, injectables, IV etc)
This is not investment advice.
